GlassScriptPhysician profile
Michael G Casagrande
NPI 1427163955
$19,133.03
in general payments reported to CMS, 2019-2025
74 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,720 · 2020: $2,615 · 2021: $2,793 · 2022: $2,740 · 2023: $3,382 · 2024: $2,676 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,215 · Education: $51.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,214.81 |
| Education | $51.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,634.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,513.30 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,499.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,492.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,326.90 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $1,091.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $997.85 | 2021-2025 | |
| Abbvie INC. | $684.37 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Jazz Pharmaceuticals INC. | $444.44 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $430.03 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.64 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $370.83 | 2019-2022 | |
| Antares Pharma, INC. | $363.85 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Axsome Therapeutics, INC. | $359.07 | 2022-2025 | Sunosi, Auvelity |
| Allergan, INC. | $354.35 | 2019-2021 |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Casagrande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.